MedTrace Logo

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

NCT00421213 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-07-19

No results posted yet for this study

Summary

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Conditions

  • Hematologic Neoplasms
  • Bone Marrow Neoplasms
  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Darinaparsin

300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421213 on ClinicalTrials.gov